CVC Funds Enter Exclusive Negotiations with Warburg Pincus for Significant Minority Stake in Sebia

"Willkie is advising CVC funds in exclusive negotiations with Warburg Pincus for the sale of a significant minority stake in Sebia, along with a reinvestment by CVC in the company. Existing shareholders, including CVC, La Caisse, and Téthys Invest, will remain significant investors. Sebia specializes in in vitro diagnostics for various diseases. The transaction is subject to employee consultation and regulatory approvals, with closure expected in the first quarter of 2026. The advisory team from Willkie in Paris is led by Cédric Hajage."

**Press Release Summary** Willkie Farr & Gallagher LLP advised CVC Capital Partners in their exclusive negotiations with Warburg Pincus regarding the sale of a significant minority stake in Sebia and the reinvestment of CVC funds into the company. The transaction involves CVC entering into exclusive negotiations to sell a substantial minority interest in Sebia, a global player in in vitro diagnostics that provides equipment and reagents for the screening and monitoring of various diseases, primarily in oncology, diabetes, hemoglobinopathies, autoimmune and infectious diseases, as well as other rare pathologies. Existing shareholders, including CVC, La Caisse (formerly CDPQ), and Téthys Invest, will continue to be significant investors in Sebia. The completion of the transaction is subject to the finalization of employee consultation processes and obtaining the usual regulatory approvals, with closure not expected before the first quarter of 2026. The Willkie team in Paris advising CVC is led by partner Cédric Hajage, alongside corporate partners Grégoire Finance and Hugo Nocerino, as well as corporate associates Mathilde Faure, Sarah Bibas, and Floriane Teillet.

CVC Funds Enter Exclusive Negotiations with Warburg Pincus for Significant Minority Stake in Sebia

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads